During the 2nd European CAR T Cell Meeting in Sitges, ES, the Multiple Myeloma Hub was delighted to speak to Bregje Verhoeven from European Society for Blood and Marrow Transplantation, NL. We asked: What impact does CAR T therapy have on patient quality of life?
Bregje Verhoeven explains that quality of life (QoL) after CAR T therapy is yet to be elucidated as we do not have enough data yet. She talks about the importance of implementing the patient-reported outcomes into clinical trials. Bregje Verhoeven also discusses the patient treatment teams and their role in improving patient QoL and various other factors such as emotional and financial burdens that influence the patients QoL.